Acetylcholine Receptor Antibody Reflexive Panel
Ordering Recommendation

Preferred reflexive panel for diagnosing myasthenia gravis. Panel contains binding, blocking, and modulating antibodies.

Quantitative Radioimmunoassay/Semi-Quantitative Flow Cytometry
3-7 days
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
ARUP Consult®
Disease Topics
Specimen Required
Patient Preparation
Serum separator tube. 
Specimen Preparation
Separate serum from cells ASAP or within 2 hours of collection. Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.5 mL) 
Storage/Transport Temperature
Unacceptable Conditions
Contaminated, hemolyzed, or severely lipemic specimens. 
After separation from cells: Ambient: 2 hours; Refrigerated: 2 weeks; Frozen: 1 year (avoid repeated freeze/thaw cycles) 
Reference Interval
Test Number
Reference Interval
0080009Acetylcholine Receptor Binding Antibody
Negative0.0-0.4 nmol/L
Positive0.5 nmol/L or greater

0099580Acetylcholine Receptor Blocking AntibodyEffective November 18, 2013
Negative:0-26% blocking
Indeterminate:27-41% blocking
Positive:42% or greater blocking

0099521Acetylcholine Receptor Modulating AntibodyEffective August 20, 2012
Negative0-45% modulating
Positive46% or greater modulating

Interpretive Data
Approximately 85-90 percent of patients with myasthenia gravis (MG) express antibodies to the acetylcholine receptor (AChR), which can be divided into binding, blocking, and modulating antibodies. Binding antibody can activate complement and lead to loss of AChR. Blocking antibody may impair binding of acetylcholine to the receptor, leading to poor muscle contraction. Modulating antibody causes receptor endocytosis resulting in loss of AChR expression, which correlates most closely with clinical severity of disease. Approximately 10-15 percent of individuals with confirmed myasthenia gravis have no measurable binding, blocking, or modulating antibodies.

Compliance Statement B: For laboratory developed tests not using a RUO kit, and for FDA approved, cleared or 510(k) exempt assays with alterations. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

If Acetylcholine Receptor Binding Antibody result is greater than 0.4 nmol/L or Acetylcholine Receptor Blocking Antibody result is greater than 26 percent, then Acetylcholine Receptor Modulating Antibody (ARUP test code 0099521) will be added. Additional charges apply.
Hotline History
CPT Code(s)
83519; 83516; if reflexed, add 83516
Component Test Code*Component Chart NameLOINC
0080009Acetylcholine Binding Antibody11034-6
0099580Acetylcholine Blocking Antibody42937-3
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
  • AChR Antibody
  • AChR reflex panel
  • Muscle nicotinic Acetylcholine Receptor (AChR) Binding Antibody
  • Myasthenia Gravis Antibodies
  • Myasthenia Gravis Antibodies Reflex